Search

Your search keyword '"Afdhal, N."' showing total 505 results
Start Over Author "Afdhal, N."
505 results on '"Afdhal, N."'

51. Whole exome sequencing identifies rare nonsense mutations enriched among patients with advanced fibrosis due to nonalcoholic steatohepatitis

Author

Shea, P.R., primary, Sanyal, A., additional, Harrison, S., additional, Ratziu, V., additional, Loomba, R., additional, Caldwell, S., additional, Kleinstein, S., additional, Mccolgan, B., additional, Subramanian, M., additional, Mchutchison, J.G., additional, Myers, R., additional, Goodman, Z., additional, Abdelmalek, M., additional, Bosch, J., additional, Afdhal, N., additional, and Goldstein, D., additional

Published
2018
Full Text
View/download PDF

52. The association of circulating microRNAs (miRs) with liver fibrosis stage and the impact of selonsertib treatment in patients with NASH

Author

Charlton, M., primary, Diehl, A.M., additional, Sarkar, N., additional, LI, B., additional, Wang, L., additional, Billin, A., additional, Djedjos, S., additional, Subramanian, M., additional, Myers, R., additional, Afdhal, N., additional, Caldwell, S., additional, Goodman, Z., additional, and Loomba, R., additional

Published
2018
Full Text
View/download PDF

53. Effectiveness of sofosbuvir and ledipasvir/sofosbuvir based regimens in hepatitis C virus genotype 3 infection: real-world data from Georgian hepatitis C elimination program

Author

Tsertsvadze, T., primary, Chkhartishvili, N., additional, Abutidze, A., additional, Sharvadze, L., additional, Kerashvili, V., additional, Kamkamidze, G., additional, Zakalashvili, M., additional, Skaggs, B., additional, Gvinjilia, L., additional, Shadaker, S., additional, Nasrullah, M., additional, Gamkrelidze, A., additional, Kvaratskhelia, V., additional, Zeuzem, S., additional, Afdhal, N., additional, Arora, S., additional, Thornton, K., additional, and Averhoff, F., additional

Published
2018
Full Text
View/download PDF

55. Dose response and safety of the daily, oral RIG-I agonist Inarigivir (SB 9200) in treatment naïve patients with chronic hepatitis B: results from the 25mg and 50mg cohorts in the ACHIEVE trial

Author

Yuen, M.-F., primary, Elkashab, M., additional, Chen, C.-Y., additional, Coffin, C., additional, Fung, S., additional, Greenbloom, S., additional, Jang, J.W., additional, Jeng, R.W.-J., additional, Kim, D.J., additional, Kim, Y.J., additional, Kim, W., additional, Lee, K.S., additional, Lim, Y.-S., additional, Ramji, A., additional, Iyer, R., additional, Macfarlane, C., additional, Jackson, K., additional, Locarnini, S., additional, Afdhal, N., additional, and Chan, H., additional

Published
2018
Full Text
View/download PDF

57. Prediction of fibrosis improvement in patients with advanced fibrosis due to NASH using a machine learning approach: Unravelling the placebo response

Author

Sanyal, A., primary, Nguyen, T., additional, Wang, L., additional, Xiao, Y., additional, Jia, C., additional, Xu, R., additional, Djedjos, S., additional, Subramanian, M., additional, Myers, R., additional, Ratziu, V., additional, Afdhal, N., additional, Bosch, J., additional, Harrison, S., additional, and Goodman, Z., additional

Published
2018
Full Text
View/download PDF

62. Serum bile acids are markedly elevated in patients with compensated cirrhosis due to nonalcoholic steatohepatitis (NASH)

Author

Sanyal, A., primary, Harrison, S., additional, Charlton, M., additional, Caldwell, S., additional, Chuang, J., additional, Wang, L., additional, Chen, G., additional, Chung, C., additional, Djedjos, S., additional, Myers, R., additional, Afdhal, N., additional, Bosch, J., additional, Ratziu, V., additional, and Loomba, R., additional

Published
2018
Full Text
View/download PDF

63. Hepatitis C care cascade in the country of Georgia after 2 years of starting national hepatitis C elimination program

Author

Tsertsvadze, T., primary, Gamkrelidze, A., additional, Chkhartishvili, N., additional, Gvinjilia, L., additional, Abutidze, A., additional, Sharvadze, L., additional, Butsashvili, M., additional, Metreveli, D., additional, Ezugbaia, M., additional, Kuchuloria, T., additional, Shadaker, S., additional, Nasrullah, M., additional, Skaggs, B., additional, Kvaratskhelia, V., additional, Zeuzem, S., additional, Afdhal, N., additional, Arora, S., additional, Thornton, K., additional, and Averhoff, F., additional

Published
2018
Full Text
View/download PDF

64. Real world effectiveness of Ledipasvir/Sofosbuvir based regimens in hepatitis C virus genotype 1,2 and 3 infection within national hepatitis C elimination program in the country of Georgia

Author

Tsertsvadze, T., primary, Chkhartishvili, N., additional, Abutidze, A., additional, Sharvadze, L., additional, Kerashvili, V., additional, Butsashvili, M., additional, Zarkua, J., additional, Skaggs, B., additional, Gvinjilia, L., additional, Shadaker, S., additional, Nasrullah, M., additional, Gamkrelidze, A., additional, Kvaratskhelia, V., additional, Afdhal, N., additional, Zeuzem, S., additional, Arora, S., additional, Thornton, K., additional, and Averhoff, F., additional

Published
2018
Full Text
View/download PDF

66. Irish Society of Gastroenterology — Winter Meeting Held at Freeman Auditorium, Mater Misericordiae Hospital, Dublin on Friday, 20th and Saturday, 21st November, 1987

Author

Brown, J. S., Humphreys, W. W., Parks, T. G., Dolan, C., O’Farrelly, C., Weiser, H., Whelan, A., Weir, D. G., Feighery, C., Mackle, E. J., Parks, T. G., Pender, D., Moghissi, K., Geraghty, J. G., Anderson, W. J., Carter, D. C., Cuddihy, A., Jenkins, D., Whelton, M. J., Gilligan, D., Cafferkey, M., Keane, C., O’Morain, C., MacMathuna, P., O’Connor, M. K., O’Connor, M. P., Freyne, P., Keeling, P. W. N., Deasy, J. M., Lavelle, J. P., Clery, A. P., Mackle, E. J., Sawhney, B. B., Mills, J. O. M., Parks, T. G., O’Connor, H. J., Ellis, W. R., Manning, A. P., Lintott, D. L., McMahon, M. J., Axon, A. T. B., Stuart, R., Byrne, P., Keeling, P., Connolly, J., Keane, R. M., Hennessy, T. P. J., Courtney, M. G., McDonald, G. S. A., Hourihane, D. O’B., Weir, D. G., McGibney, Carol, Darzi, A., Monson, J. R. T., Morrison, P., Tanner, W. A., Keane, F. B., Tobin, A., Gilligan, D., Hutchinson, L., Casey, E., McKenna, D., Keane, C. T., Sweeney, E. A., O’Morain, C. A., MacMathuna, P., Foley, B., O’Reilly, T., Chua, A., Feely, J., Keeling, P. W. N., Kelly, C. P., Dolan, C., Feighery, C., Weir, D. G., Darzi, A., Monson, J. R. T., Kay, E., Hurley, C. D., Tanner, W. A., Keane, F. B. V., Deasy, J. M., Carr, J., Clery, A. P., O’Donoghue, D. P., Duffy, M. J., Afdhal, N. H., Creagh, T., Broe, P., Bouchier-Hayes, D., Moran, B. J., Busch, I., Singleton, J. McL, Johnston, P., O’Brien, M., Dervan, P., Crowe, J., Lennon, J., Carney, D. N., Bourke, S., Murphy, B., Maher, K., Stafford, F., O’Morain, C., Daly, C. A., Gorey, T. F., Lavelle, J., Coakley, J. B., Bouchier-Hayes, D., Peng, S. Y., Parks, T. G., Maxwell, W. J., Keating, J., Hogan, F. P., McDonald, G. S. A., Keeling, P. W. N., Coyle, D., Gorey, T. F., Leahy, A. L., Fitzpatrick, P., Bouchier-Hayes, D., O’Donoghue, D. P., Duffy, M. J., Afdhal, N. H., Waldron, D. J., Gill, R. C., Bowes, K. L., Gallagher, R. B., Cervi, P., Dolan, C., Kelly, J., Weir, D. G., Feighery, C., Lavelle, E. M., Stevens, F. M., Duffy, B. S., Coghlan, J. G., Gilligan, D., Humphries, H., McKenna, D., Sweeney, E., Keane, C., O’Morain, C., Murray, D., O’Mahony, S., Buchanan, K., and Whelton, M.

Published
1988
Full Text
View/download PDF

67. Irish Society of Gastroenterology: Proceedings of the Irish Society of Gastroenterology, 24th/25th May, 1985

Author

Whelton, M. J., Fitzgerald, P., Ritchie, E., Jenkins, D., Leahy, A. L., Nee, J. M., Wait, R. B., Pollock, T. W., Collins, B. J., Elliott, H., Sloan, J. M., McFarland, R. J., Love, A. H. G., Mac Mathúna, P., O’Reilly, T., Kelleher, D., Keeling, P. W. N., Feely, J., West, B., Byrne, P., Sheahan, G., Stephens, R., Hennessy, T., Doyle, C. T., Bloomfield, F. J., Maxwell, W. J., Hogan, F. P., Walsh, J. P., Duffy, M. J., O’Sullivan, F., O’Donoghue, D., Afdhal, N., Collins, J. S. A., Kennedy, T. L., Buchanan, K. D., Johnston, C. F., O’Hare, M. M. T., Walsh, T. N., Alderson, D., Tate, P., Lavells, M. I., Ryan, P., Lennon, G., Walsh, D., Hegarty, J. H., Keane, F. B. V., Tanner, W. A., Afdhal, N. H., Long, A. A., Tobbia, I., Tobin, B., O’Rafferty, R., O’Donoghue, D. P., Deasy, J., Clinton, O., Burke, G., Delaney, P., O’Mahony, C., O’Farrelly, C., Weir, D. G., Finch, T., Feighery, C. F., Traynor, O. J., Byrne, P. J., Hennessy, T. P. J., Lombard, M., Murray, F. E., Connolly, G., Lennon, J., Crowe, J., McCann, A., Seymour, C., Broe, P. J., Bouchier-Hayes, D. J., Bloomfield, F. F., O’Farrelly, Cliona, Stevens, F., McCarthy, C., Feighery, C., McKee, C. M., McMillan, S. A., Dawson, A. T., O’Toole, J., Haire, Margaret, Callender, M. E., Fulton, T. T., McEntee, G. P., Duignan, J. P., O’Malley, E., Graeme-Cook, F., O’Farrelly, G., O’B Hourihane, D., Fitzgerald, R., Dervan, P., Lennon, J. R., Moran, B., Delaney, P. V., Kelly, J., O’Shea, B., O’Dorioghue, D. P., Keeling, P., Stuart, R., Stewart, R. J., Parks, T. G., Devery, R., Tomkin, G. H., McKay, P. A., O’Connor, M., Miller, S., McDonald, G., Fryene, P. J., Martin, L., Ryan, F., Collum, C., Lavelle, J., Ennis, J., Doyle, J. S., O’Connor, H. J., Schorah, C. J., Axon, A. T. R., Riley, S. E., Garner, R. C., Burke, O., Long, J. P., and Lennon, F.

Published
1986
Full Text
View/download PDF

68. Irish Society of Gastroenterology Proceedings of the Summer Meeting of the Irish Society of Gastroenterology, held in Universitly College, Cork on Friday 6th and Saturday 7th June, 1986

Author

Moorehead, R. J., Donaldson, John, McKelvey, S. T. D., Drumm, J., Harding, L. K., Clarke, E. A., Alexander-Williams, J., Donovan, I. A., Lorigan, G., Butler, F., Broe, P. J., O’Hara, Martin J., McCormick, P. Aidan, Molloy, Aishling, McGrath, Derek, O’Donoghue, Diarmuid P., Farrell, T., O’Donoghue, D., Daly, L., Masterson, J. B., Breen, E. G., Coughlan, J., Connolly, C. E., Stevens, F. M., McCarthy, C. F., Tobin, M. V., Fiskan, R. A., Dissory, R. T., Gilmore, I. T., McCormick, Deirdre, Cullen, Alan, McCormick, P. Aidan, Towers, Robert P., Keane, R. M., Coleman, J. E., Clery, A. P., Keane, T., Dillon, B., Afdhal, N. H., McCormick, C. J., Stevens, F. M., Connolly, C. E., McCarthy, C. F., Hitchcock, H., Waldron, David J., Fitzgerald, Raymond J., Quigley, E. M. M., Hall, L., Turnberg, L. A., Brennan, F. N., Buchanan, K. D., Afdhal, N. H., Duffy, M. J., Thornton, A., O’Sullivan, F., O’Donoghue, D. P., Mullen, P., O’Connor, B., Lombard, M., Coakley, J. B., Crowe, J., Lennon, J. R., Keeling, P., Hennessy, T. P. J., Gleeson, D., Quereshi, Y., Murphy, G. M., Dowling, R. H., O’Connor, H. J., Dixon, M. F., Wyatt, J. I., Axon, A. T. R., Gillen, P., Keeling, P., Byrne, P. J., West, A. B., Hennessy, T. P. J., Walsh, T. N., O’Higgins, N., Quigley, E. M. M., Turnberg, L. A., O’Hara, Martin J., McCormick, P. Aidan, McGowan, Katherine, Miller, Joan C., Masterson, James, O’Donoghue, Diarmuid P., Courtney, M. G., McPartlin, J. M., Scott, J. M., Weir, D. G., Wilson, B. G., Howe, J. P., Parks, T. G., McCormick, P. A., Ramsay, N., Afdhal, N., Tubridy, P., Shattock, A. G., Hillery, I., O’Donoghue, D. P., Collins, J. S. A., Knill-Jones, R. P., Crean, G. P., Love, A. H. G., Quigley, E. M. M., Hole, D. J., Gillis, C. R., Watkinson, G., Moore, Helena, Moylan, H. E., Fottrell, P. F., Stevens, F. M., Brady, H. R., Godson, C., Ryan, M. P., Bourke, S., FitzGerald, M. X., McCormick, P. A., O’Farrelly, C., Graeme-Cook, F., Finch, A., Feighery, C., Weir, D. G., O’Donoghue, D. P., FitzGerald, M. X., Maxwell, W. J., Walsh, J. P., Hogan, F. P., Kennedy, N. P., Keeling, P. W. N., Sheil, O., Barniville, H., and Fitzgerald, O.

Published
1987
Full Text
View/download PDF

71. Real-world effectiveness of sofosbuvir and ledipasvir/sofosbuvir based regimens in hepatitis C virus genotype 3 infection within national hepatitis C elimination program in the country of Georgia

Author

Tsertsvadze, T., primary, Chkhartishvili, N., additional, Sharvadze, L., additional, Abutidze, A., additional, Arora, S., additional, Thornton, K., additional, Kerashvili, V., additional, Zhamutashvili, M., additional, Ezugbaia, M., additional, Svanidze, M., additional, Darakhvelidze, M., additional, Kvaratskhelia, V., additional, Afdhal, N., additional, and Zeuzem, S., additional

Published
2017
Full Text
View/download PDF

72. Changes in fibrosis, but not the NAFLD Activity Score (NAS), are associated with disease progression in patients with nonalcoholic steatohepatitis (NASH) and advanced fibrosis

Author

Sanyal, A., primary, Harrison, S., additional, Ratziu, V., additional, Abdelmalek, M., additional, Diehl, A., additional, Caldwell, S., additional, Shiffman, M., additional, Aguilar, R., additional, Jia, C., additional, McColgan, B., additional, Myers, R., additional, Subramanian, M., additional, McHutchison, J., additional, Muir, A., additional, Afdhal, N., additional, Bosch, J., additional, and Goodman, Z., additional

Published
2017
Full Text
View/download PDF

74. Impact of modest weight reduction on liver histology, portal pressure, and clinical events in patients with compensated cirrhosis due to nonalcoholic steatohepatitis

Author

Bosch, J., primary, Harrison, S., additional, Ratziu, V., additional, Shiffman, M., additional, Diehl, A., additional, Caldwell, S., additional, Rockey, D., additional, Ghalib, R., additional, Thuluvath, P., additional, Abdelmalek, M., additional, Aguilar, R., additional, Jia, C., additional, Mccolgan, B., additional, Myers, R., additional, Subramanian, M., additional, McHutchison, J., additional, Goodman, Z., additional, Afdhal, N., additional, and Sanyal, A., additional

Published
2017
Full Text
View/download PDF

75. Efficacy and safety of simtuzumab for the treatment of nonalcoholic steatohepatitis with bridging fibrosis or cirrhosis: results of two phase 2b, dose-ranging, randomized, placebo-controlled trials

Author

Sanyal, A., primary, Abdelmalek, M.F., additional, Diehl, A.M., additional, Caldwell, S., additional, Shiffman, M.L., additional, Ghalib, R., additional, Lawitz, E., additional, Rockey, D.C., additional, Schall, R.A., additional, Jia, C., additional, McColgan, B.J., additional, Myers, R., additional, Subramanian, G.M., additional, McHutchison, J.G., additional, Ratziu, V., additional, Afdhal, N., additional, Goodman, Z., additional, Harrison, S.A., additional, and Bosch, J., additional

Published
2017
Full Text
View/download PDF

76. Efficacy and safety of simtuzumab for the treatment of primary sclerosing cholangitis: results of a phase 2b, dose-ranging, randomized, placebo-controlled trial

Author

Muir, A., primary, Goodman, Z., additional, Levy, C., additional, Janssen, H., additional, Montano-Loza, A., additional, Bowlus, C., additional, Ding, D., additional, Jia, C., additional, McColgan, B., additional, Myers, R., additional, Subramanian, M., additional, McHutchison, J., additional, Manns, M., additional, Chapman, R., additional, Afdhal, N., additional, and Eksteen, B., additional

Published
2017
Full Text
View/download PDF

79. Impact of weight reduction on serum markers and liver histology including progression to cirrhosis in patients with nonalcoholic steatohepatitis (NASH) and bridging fibrosis

Author

Ratziu, V., primary, Sanyal, A., additional, Torres, D., additional, Hinrichsen, H., additional, Serfaty, L., additional, Bambha, K., additional, Jayakumar, S., additional, Goodman, Z., additional, Abdelmalek, M., additional, Aguilar, R., additional, Jia, C., additional, Mccolgan, B., additional, Myers, R., additional, Subramanian, M., additional, McHutchison, J., additional, Afdhal, N., additional, and Harrison, S., additional

Published
2017
Full Text
View/download PDF

82. Telaprevir for previously untreated chronic hepatitis C virus infection

Author

Jacobson I. M., McHutchison J. G., Dusheiko G., Di Bisceglie A. M., Reddy K. R., Bzowej N. H., Marcellin P., Muir A. J., Ferenci P., Flisiak R., George J., Rizzetto M., Shouval D., Sola R., Terg R. A., Yoshida E. M., Adda N., Bengtsson L., Sankoh A. J., Kieffer T. L., George S., Kauffman R. S., Zeuzem S., ADVANCE Study Team: Gadano A., Terg R., Bell S., Cheng W., Crawford D., Dore G., MacDonald G., Roberts S., Gschwantler M., Laferl H., Maieron A., Heathcote J., Kaita K., Myers R., Sherman M., Yoshida E., Barange K., Couzigou P., Pawlotsky J. M., Pol S., Serfaty L., Trépo C., Zarski J. P., Berg T., Buggisch P., Diepolder H., Goeser T., Mauss S., Rasenack J., Schmidt W., Wedemeyer H., Baruch Y., Ben Ari Z., Maor Y., Safadi R., Zuckerman E., Colombo M., Baka Cwierz B., Gladysz A., Janczewska Kazek E., Jablkowski M., Krycka W., Diago M., Esteban Mur R., Sanchez Tapias J., Brown A., Fox R., Afdhal N., Arora S., Bennett M., Bernstein D., Bloomer J., Bochan M., Bonkovsky H., Brady C., Brown R., Bzowej N., Cochran J., Chasen R., Davis G., De Jesus E., Di Bisceglie A., Dienstag J., Dieterich D., Etzkorn K., Everson G., Fried M., Freilich B., Ghalib R., Gitlin N., Godofsky E., Gordon S., Hassanein T., Jacobson I., Javadi F., Jonas M., Kilby A., Kwo P., Lawitz E., Lebovics E., Lee W., Luketic V., Maillard M., Monto A., Morgan T., Min A., Murphy M., Nelson D., Northup P., Nyberg L., Pockros P., Poordad F., Poulos J., Reddy R., Rodriguez Torres M., Satyanarayana R., Schiff E., Schwartz H., Shaikh O., Sheikh M., Sherman K., Smith J., Strohecker J., Sulkowski M., Szabo G., Te H., Terrault N., Tsai N., Vargas H., Vierling J., Wruble L., Younossi Z., Zein N., ANDREONE, PIETRO, Jacobson I.M., McHutchison J.G., Dusheiko G., Di Bisceglie A.M., Reddy K.R., Bzowej N.H., Marcellin P., Muir A.J., Ferenci P., Flisiak R., George J., Rizzetto M., Shouval D., Sola R., Terg R.A., Yoshida E.M., Adda N., Bengtsson L., Sankoh A.J., Kieffer T.L., George S., Kauffman R.S., Zeuzem S., ADVANCE Study Team: Gadano A., Terg R., Bell S., Cheng W., Crawford D., Dore G., MacDonald G., Roberts S., Gschwantler M., Laferl H., Maieron A., Heathcote J., Kaita K., Myers R., Sherman M., Yoshida E., Barange K., Couzigou P., Pawlotsky J.M., Pol S., Serfaty L., Trépo C., Zarski J.P., Berg T., Buggisch P., Diepolder H., Goeser T., Mauss S., Rasenack J., Schmidt W., Wedemeyer H., Baruch Y., Ben-Ari Z., Maor Y., Safadi R., Zuckerman E., Andreone P., Colombo M., Baka-Cwierz B., Gladysz A., Janczewska-Kazek E., Jablkowski M., Krycka W., Diago M., Esteban-Mur R., Sanchez-Tapias J., Brown A., Fox R., Afdhal N., Arora S., Bennett M., Bernstein D., Bloomer J., Bochan M., Bonkovsky H., Brady C., Brown R., Bzowej N., Cochran J., Chasen R., Davis G., De Jesus E., Di Bisceglie A., Dienstag J., Dieterich D., Etzkorn K., Everson G., Fried M., Freilich B., Ghalib R., Gitlin N., Godofsky E., Gordon S., Hassanein T., Jacobson I., Javadi F., Jonas M., Kilby A., Kwo P., Lawitz E., Lebovics E., Lee W., Luketic V., Maillard M., Monto A., Morgan T., Min A., Murphy M., Nelson D., Northup P., Nyberg L., Pockros P., Poordad F., Poulos J., Reddy R., Rodriguez-Torres M., Satyanarayana R., Schiff E., Schwartz H., Shaikh O., Sheikh M., Sherman K., Smith J., Strohecker J., Sulkowski M., Szabo G., Te H., Terrault N., Tsai N., Vargas H., Vierling J., Wruble L., Younossi Z., and Zein N.

Subjects
Adult, Male, medicine.medical_specialty, CHRONIC HEPATITIS C, Telaprevir, ANTIVIRAL TREATMENT, Serine Proteinase Inhibitors, Hepatitis C virus, Hepacivirus, Interferon alpha-2, medicine.disease_cause, Gastroenterology, Antiviral Agents, Polyethylene Glycols, chemistry.chemical_compound, Young Adult, Double-Blind Method, Internal medicine, Boceprevir, medicine, Humans, Beclabuvir, Aged, business.industry, Ribavirin, Danoprevir, Interferon-alpha, virus diseases, General Medicine, Hepatitis C, Sequence Analysis, DNA, Hepatitis C, Chronic, Middle Aged, Viral Load, medicine.disease, Ombitasvir, Recombinant Proteins, digestive system diseases, Logistic Models, chemistry, Immunology, RNA, Viral, Drug Therapy, Combination, Female, business, Oligopeptides, medicine.drug
Abstract

A B S T R AC T Background In phase 2 trials, telaprevir, a hepatitis C virus (HCV) genotype 1 protease inhibitor, in combination with peginterferon–ribavirin, as compared with peginterferon–ribavirin alone, has shown improved efficacy, with potential for shortening the duration of treatment in a majority of patients. Methods In this international, phase 3, randomized, double-blind, placebo-controlled trial, we assigned 1088 patients with HCV genotype 1 infection who had not received previous treatment for the infection to one of three groups: a group receiving telaprevir combined with peginterferon alfa-2a and ribavirin for 12 weeks (T12PR group), followed by peginterferon–ribavirin alone for 12 weeks if HCV RNA was undetectable at weeks 4 and 12 or for 36 weeks if HCV RNA was detectable at either time point; a group receiving telaprevir with peginterferon–ribavirin for 8 weeks and placebo with peginterferon–ribavirin for 4 weeks (T8PR group), followed by 12 or 36 weeks of peginterferon–ribavirin on the basis of the same HCV RNA criteria; or a group receiving placebo with peginterferon–ribavirin for 12 weeks, followed by 36 weeks of peginterferon–ribavirin (PR group). The primary end point was the proportion of patients who had undetectable plasma HCV RNA 24 weeks after the last planned dose of study treatment (sustained virologic response). Results Significantly more patients in the T12PR or T8PR group than in the PR group had a sustained virologic response (75% and 69%, respectively, vs. 44%; P

Published
2011

85. Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection

Author

Sulkowski, Mark S., primary, Vargas, Hugo E., additional, Di Bisceglie, Adrian M., additional, Kuo, Alexander, additional, Reddy, K. Rajender, additional, Lim, Joseph K., additional, Morelli, Giuseppe, additional, Darling, Jama M., additional, Feld, Jordan J., additional, Brown, Robert S., additional, Frazier, Lynn M., additional, Stewart, Thomas G., additional, Fried, Michael W., additional, Nelson, David R., additional, Jacobson, Ira M., additional, Afdhal, N., additional, Alam, I., additional, Ben-Ari, Z., additional, Bredfeldt, J., additional, Brown, R.S., additional, Chung, R.T., additional, Darling, J., additional, Harlan, W., additional, Di Bisceglie, A.M., additional, Dickson, R.C., additional, Elbeshbeshy, H.A., additional, Everson, G., additional, Feld, J., additional, Fenkel, J.M., additional, Fried, M.W., additional, Galati, J., additional, Gordon, S.C., additional, Hassan, M., additional, Hawkins, T.N., additional, Hinestrosa, F., additional, Jacobson, I.M., additional, Kerr, C.A., additional, Kuo, A., additional, Kwo, P.Y., additional, Levitsky, J., additional, Lim, J., additional, Lok, A.S., additional, Mailliard, M., additional, Manns, M.P., additional, Morelli, G., additional, Muir, A.J., additional, Nelson, D., additional, O’Leary, J.G., additional, Pearlman, B.L., additional, Pockros, P., additional, Ramani, A., additional, Reau, N., additional, Reddy, K.R., additional, Schiff, E.R., additional, Sherman, K.E., additional, Shiffman, M.L., additional, Smith, C., additional, Spivey, J.R., additional, Sterling, R.K., additional, Sulkowski, M.S., additional, Szabo, G., additional, Terrault, N.A., additional, Trautwein, C., additional, Vargas, H.E., additional, Watts, K., additional, Williams, A., additional, and Zeuzem, S., additional

Published
2016
Full Text
View/download PDF

86. Antiviral Efficacy and Host Immune Response Induction with SB 9200, an Oral Prodrug of the Dinucleotide SB 9000, in Combination with Entecavir in the Woodchuck Model of Chronic Hepatitis B

Author

Korolowicz, K., primary, Balarezo, M., additional, Iyer, R., additional, Padmanabhan, S., additional, Cleary, D., additional, Gimi, R., additional, Sheri, A., additional, Suresh, M., additional, Yon, C., additional, Tucker, R., additional, Afdhal, N., additional, and Menne, S., additional

Published
2016
Full Text
View/download PDF

87. SOF/VEL for 12 Weeks Results in High SVR12 Rates in Subjects with Negative Predictors of Response to Treatment: An Integrated Analysis of Efficacy from the Astral-1, Astral-2 and Astral-3 Studies

Author

Agarwal, K., primary, Patel, K., additional, Samuel, D., additional, Bourliere, M., additional, Younes, Z., additional, Morgan, T., additional, Strasser, S., additional, Leggett, B., additional, Liu, L., additional, Ding, X., additional, McNally, J., additional, Osinusi, A., additional, Brainard, D., additional, Subramanian, M., additional, and Afdhal, N., additional

Published
2016
Full Text
View/download PDF

88. Genome-Wide Association Study of Clinically Significant Portal Hypertension in Patients with Nonalcoholic Steatohepatitis and Advanced Fibrosis

Author

Shea, P.R., primary, Sanyal, A., additional, Rockey, D.C., additional, Loomba, R., additional, Diehl, A.M., additional, Kleinstein, S.E., additional, Myers, R.P., additional, Mani Subramanian, G., additional, McHutchison, J.G., additional, Abdelmalek, M.F., additional, Ratziu, V., additional, Afdhal, N., additional, Harrison, S., additional, Bosch, J., additional, and Goldstein, D.B., additional

Published
2016
Full Text
View/download PDF

89. PNPLA3 Variants Confer an Increased Risk of Advanced Fibrosis Due to Non-Alcoholic Steatohepatitis

Author

Shea, P.R., primary, Sanyal, A., additional, Harrison, S., additional, Ratziu, V., additional, Loomba, R., additional, Caldwell, S., additional, Diehl, A.M., additional, Kleinstein, S.E., additional, Myers, R.P., additional, Mani Subramanian, G., additional, McHutchison, J.G., additional, Abdelmalek, M.F., additional, Bosch, J., additional, Afdhal, N., additional, and Goldstein, D.B., additional

Published
2016
Full Text
View/download PDF

91. Correlation between the Hepatic Venous Pressure Gradient and Alpha-Smooth Muscle Actin (SMA) Expression in Patients with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis

Author

Sanyal, A., primary, Goodman, Z., additional, Harrison, S., additional, Rockey, D.C., additional, Diehl, A.M., additional, Caldwell, S., additional, Shiffman, M.L., additional, Thuluvath, P., additional, Myers, R.P., additional, Mani Subramanian, G., additional, McHutchison, J.G., additional, Abdelmalek, M.F., additional, Ratziu, V., additional, Afdhal, N., additional, and Bosch, J., additional

Published
2016
Full Text
View/download PDF

94. HCV Eradication Results in Reduction of Hepatic Venous Pressure Gradient 48 Weeks after End of Treatment; Final Results of the Study of Sofosbuvir plus Ribavirin in Patients with Cirrhosis and Portal Hypertension

Author

Afdhal, N., primary, Asselah, T., additional, Everson, G.T., additional, Bosch, J., additional, De-Oertel, S., additional, Brainard, D.M., additional, McHutchison, J.G., additional, Yang, Y., additional, Watt, K.D., additional, Curry, M., additional, and Gane, E., additional

Published
2016
Full Text
View/download PDF

95. Resistance Analyses for Ledipasvir/Sofosbuvir Containing Regimens in Patients Infected with Chronic HCV who Have Advanced Liver Disease or are Post Liver Transplant (Solar-1 & 2 Studies)

Author

Charlton, M., primary, Manns, M., additional, Dvory-Sobol, H., additional, Svarovskaia, E., additional, Doehle, B., additional, Arterburn, S., additional, Yun, C., additional, Brainard, D.M., additional, Mchutchison, J.G., additional, Miller, M.D., additional, Mo, H., additional, Afdhal, N., additional, and Mutimer, D., additional

Published
2016
Full Text
View/download PDF

98. Hepatic CD1d expression in hepatitis C virus infection and recognition by resident proinflammatory CD1d-reactive T cells

Author

DURANTE MANGONI, Emanuele, Wang RJ, Shaulov A, He Q, Nasser I, Afdhal N, Koziel MJ, Exley MA, DURANTE MANGONI, Emanuele, Wang, Rj, Shaulov, A, He, Q, Nasser, I, Afdhal, N, Koziel, Mj, and Exley, Ma

Subjects
lipids (amino acids, peptides, and proteins), hemic and immune systems, chemical and pharmacologic phenomena
Abstract

A subset of CD161(+)CD56(+/-) NKT cells can recognize glycolipids presented by CD1d and positively or negatively regulate inflammatory responses, including those implicated in several models of hepatitis. CD1d is expressed at very low levels in the healthy liver, but there is a large fraction of CD161(+)CD56(+) NKT cells. There are high levels of nonclassical proinflammatory hepatic CD1d-reactive T cells in hepatitis C virus (HCV) infection. Hepatic inflammatory cells and biliary cells adjacent to portal tract fibrotic areas of HCV-infected donors specifically up-regulated CD1d. A hepatocyte cell line expressing minimal CD1d was efficiently recognized by hepatic CD1d-reactive T cells, suggesting a role for these cells in disease. Hepatic CD1d-reactive T cells from HCV-positive as well as negative donors produced large amounts of IFN-gamma with some IL-13, but only rarely detectable IL-4. We confirmed large numbers of hepatic CD161(+) T cells, lower levels of CD56(+) T cells, and small numbers of classic invariant NKT cells. However, hepatic CD1d-reactivity was not restricted to any of these populations. We suggest virally infected hepatic cells can process potent CD1d-presented liver Ag(s), for surveillance by resident Th1 hepatic CD1d-reactive T cells. This process may be beneficial in acute viral clearance, but in chronic infection could contribute to liver injury.

Published
2004

Catalog

Books, media, physical & digital resources
See catalog results